| ID | Title | Body | Facebook Description | Facebook image | Facebook Title | Facebook Video | Twitter Description | Twitter Image | Twitter Title | Meta tags |
|---|---|---|---|---|---|---|---|---|---|---|
| 456 | Myrl Weinberg, M.A. (2015) | Myrl Weinberg is president of the National Health Council (NHC), the only organization of its kind that provides a united voice for the more than 133 million people with chronic diseases and disabilities and their families and caregivers. Made up of more than 100 national health-related organizations and businesses, NHC’s core membership includes approximately 50 of the nation’s leading patient advocacy groups, which control its governance. Other members include professional and membership associations; nonprofit organizations with an interest in health; and major pharmaceutical, medical device, health insurance and biotechnology companies. Weinberg’s extensive career has focused on health care delivery, medical research, long-term care and related issues that affect people with chronic conditions. She has testified repeatedly before Congress and federal regulatory bodies and is a frequent speaker on the patient perspective in health policy. Weinberg has a long history of board and committee service. She is currently a member of the Observational Medical Outcomes Partnership Executive Board; the Institute of Medicine’s Value Incentives Learning Collaborative, an activity of the Roundtable on Value & Science-Driven Health Care; the board of advisors for the Center for Information and Study on Clinical Research Participation; the Robert Wood Johnson Foundation’s Aligning Forces for Quality Program National Advisory Committee; the Brookings Active Surveillance Implementation Council; and the Roche International Science and Ethics Advisory Group. Weinberg also has served on the National Library of Medicine’s board of regents’ Working Group on Clinical Trials, the Department of Health and Human Services’ National Advisory Council for Healthcare Research and Quality and the Governing Board of the International Alliance of Patients’ Organization. | ||||||||
| 455 | Pamela B. Davis, M.D., Ph.D. (2015) | Pamela B. Davis was named dean of the School of Medicine and vice president for medical affairs at Case Western Reserve University in 2007, after serving as interim dean since 2006. Previously, Davis was chief of the Pediatric Pulmonary Division at Rainbow Babies and Children’s Hospital and director of the Willard A. Bernbaum Cystic Fibrosis Research Center. She is the Arline H. and Curtis F. Garvin, M.D., research professor and chair at the School of Medicine and also is a professor of pediatrics. Davis has published more than 130 original articles and holds seven U.S. patents. She has brought novel anti-inflammatory therapies and gene therapy strategies into clinical testing for cystic fibrosis. She currently serves as principal investigator for Case Western Reserve University’s Clinical and Translational Science Award. Davis also has served on the National Diabetes and Digestive and Kidney Diseases Advisory Council and the Working Group for Human Embryonic Stem Cell Eligibility Review at the National Heart, Lung, and Blood Institute. Davis has received the Paul Di Sant’Agnese Award from the Cystic Fibrosis Foundation, the Rosenthal Prize for academic pediatrics, and the Smith College Medal. She has been named regularly in "Best Doctors in America" and "Top Doctors." She received her medical degree and doctorate in physiology and pharmacology from Duke University. | ||||||||
| 454 | Lawrence A. Soler, J.D. (March 2016) | Lawrence (Larry) A. Soler is president and CEO of the Partnership for a Healthier America (PHA). Prior to joining PHA in 2011, Soler was chief operating officer for the Juvenile Diabetes Research Foundation (JDRF), a $200 million voluntary health organization. He originally joined JDRF as a senior legislative counsel in 1998 and was promoted four times during his tenure at the organization. While leading JDRF Government Relations, the program was recognized by the National Journal as one of the most powerful interest groups in Washington, D.C. The New York Times said "not since AIDS activists stormed scientific meetings in the 1980s has a patient group done more to set the agenda of medical research." Time magazine called JDRF "one of the nation’s most forceful disease advocacy groups." Among his signature accomplishments at JDRF, Soler is credited with leading efforts that resulted in securing $1.75 billion in mandatory federal funding for type 1 diabetes research as well as founding the Coalition for the Advancement of Medical Research, which successfully prevented a federal ban in a leading medical research area. In addition, Soler served as the executive sponsor of JDRF’s Artificial Pancreas Project, an ambitious effort to accelerate the development of closed loop insulin pumps and glucose monitoring systems that affected reimbursement policy, regulatory policy, research strategy and industry partnerships. Soler received a bachelor’s degree with honors from Clark University and his juris doctor from George Washington University. He is a member of the Maryland and D.C. Bar Associations. He serves on the JDRF board of directors. | ||||||||
| 453 | Jorge L. Contreras, J.D. (February 2017) | Jorge L. Contreras is an associate professor at the University of Utah's S.J. Quinney College of Law and an Adjunct Associate Professor in the Department of Human Genetics at the School of Medicine. Professor Contreras teaches in the areas of intellectual property, law and science, and property law. His research focuses, among other things, on the development of technical standards and the use and dissemination of data generated by large-scale scientific research projects. Contreras is co-chair of the American Bar Association Section of Science & Technology Law’s Technical Standardization Committee. He previously served as a member of the National Advisory Council for Human Genome Research at NIH. Prior to joining the University of Utah, Contreras was a partner at the international law firm Wilmer Cutler Pickering Hale and Dorr LLP, where he practiced transactional and intellectual property law in Boston, London and Washington DC. He received a juris doctor from Harvard Law School and bachelor’s degrees from Rice University. | ||||||||
| 452 | Harry P. Selker, M.D., M.S.P.H. (2018) | Harry P. Selker, M.D., M.S.P.H.,is dean of the Tufts University-wide Clinical and Translational Science Institute and principal investigator on the NIH Clinical and Translational Science Award that supports it. Selker is professor of medicine at the Tufts University School of Medicine and executive director for the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center, where he is also chief of the Division of Clinical Care Research in the Department of Medicine and director of the Center for Cardiovascular Health Services Research. Selker has served on boards and as an officer for a variety of professional and educational organizations, including as president of the Society of General Internal Medicine (2011–2012), Society for Clinical and Translational Science (2010–2011), and Association for Clinical Research Training (2003–2004). He has been an active advisor in the design of clinical research graduate and training programs in the U.S. and internationally, and he is an active advocate and advisor in Washington in support of clinical research, research training and improvements in the health care delivery system. Selker maintains a medical practice at the Pratt Diagnostic Clinic at Tufts Medical Center. In his research, Selker is particularly known for a series of studies of the factors influencing emergency cardiac care and for development of “cardiac predictive instruments,” mathematical decision aids embedded into electrocardiographs, which provide emergency clinicians with predictions of key outcomes for real-time use in the clinical setting. This work has included development of a methodology for mathematical modeling of medical outcomes for risk adjustment and clinical prediction. Selker was principal investigator and study chair for the national IMMEDIATE (Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency care) Trial sponsored by the National heart, Lung and Blood Institute; the trial focused on use of intravenous GIK (glucose, insulin and potassium) delivered by paramedics in the community to reduce deaths from acute coronary syndromes and heart attack. Selker also was principal investigator for a multicenter study of error reduction approaches in emergency medical service (EMS) and emergency department care, conducted in Massachusetts communities jointly by their local hospitals and EMS systems. He has been continuously funded by federal R01 and equivalent grants for more than two decades. | ||||||||
| 451 | Geoffrey S. Ginsburg, M.D., Ph.D. (February 2017) | Geoffrey S. Ginsburg is the founding director of the Center for Genomic Medicine in the Duke Institute for Genome Sciences & Policy. He also is professor of medicine, pathology and biomedical engineering at Duke University Medical Center. Ginsburg is an internationally recognized expert in genomics and personalized medicine with more than 200 published papers and funding from NIH, the Department of Defense, the U.S. Air Force, the Defense Advanced Research Projects Agency, the Bill and Melinda Gates Foundation and industry organizations. From the faculty of Harvard Medical School, Ginsburg joined Millennium Pharmaceuticals, Inc., in 1997, where he was vice president of molecular and personalized medicine and responsible for developing pharmacogenomic and biomarker strategies for therapeutics. Awards for his research accomplishments include the Innovator in Medicine Award from Millennium and the Basic Research Achievement Award in Cardiovascular Medicine from Duke. Ginsburg is a founding and former board member of the Personalized Medicine Coalition, a senior consulting editor for the Journal of the American College of Cardiology, an editor for The HUGO Journal, an editorial advisor for Science Translational Medicine and editor of Genomic and Personalized Medicine (Elsevier). Ginsburg has been a member of the Secretary of Veterans Affairs Advisory Council on Genomic Medicine and the National Advisory Council for Human Genome Research at NIH. He currently serves as an international expert panel member for Genome Canada, a member of the Board of External Experts for the National Heart, Lung, and Blood Institute, a member of the Institute of Medicine’s Roundtable on Genome-Based Research to Human Health, and a member of the External Scientific Panel for the Pharmacogenomics Research Network. He recently was appointed to the World Economics Forum’s Global Agenda Council on Personalized and Precision Medicine. | ||||||||
| 450 | Freda C. Lewis-Hall, M.D., DFAPA (February 2017) | As Pfizer’s Chief Medical Officer, Freda Lewis-Hall leads Pfizer Medical, the division responsible for the safe, effective and appropriate use of Pfizer medicines and vaccines around the world. Before joining Pfizer in 2009, Lewis-Hall held senior leadership positions at Vertex, Bristol-Myers Squibb, Pharmacia and Lilly. Prior to joining the research-based biopharmaceutical industry, she led research projects for the National Institutes of Health and served as vice chairperson and associate professor of the Department of Psychiatry at Howard University College of Medicine. Trained as a psychiatrist, Lewis-Hall launched her medical career in frontline patient care. She is a Distinguished Fellow of the American Psychiatric Association. In 2010, Lewis-Hall was appointed the inaugural Board of Governors for the Patient-Centered Outcomes Research Institute (PCORI). She also serves on the Executive Committee of the Clinical Trials Transformation Initiative and on numerous other boards, including those of Harvard Medical School, Save the Children, and The Institute of Medicine’s Forum on Drug Discovery, Development, and Translation. Lewis-Hall earned her undergraduate degree at The Johns Hopkins University and her medical degree from Howard University College of Medicine. A passionate advocate for empowering patients through knowledge, Lewis-Hall speaks frequently in venues from TEDMED to the Essence Music Festival, appears regularly on television shows including The Doctors and Dr. Phil, and shares health information at www.gethealthystayhealthy.com | ||||||||
| 449 | Frank L. Douglas, Ph.D., M.D. (2016) | Frank L. Douglas is president and CEO at Austen BioInnovation Institute in Akron, Ohio, a biomaterials institute built on a unique collaboration of five medical and educational institutions. An award-winning industry veteran with nearly three decades of experience in health care, pharmaceuticals and entrepreneurship, Douglas serves as chief strategist for the institute, which focuses on delivering value-added patient-centered innovation and commercialization. Douglas is University Professor in the College of Polymer Science and Engineering at the University of Akron, professor of integrated medical sciences at Northeast Ohio Medical University, member of the Ewing Marion Kauffman Foundation’s board of trustees and senior partner emeritus of PureTech Ventures. He currently is the national chairman of the Value-driven Engineering and U.S. Global Competitiveness initiative, a public-private coalition made up of leaders from industry, academia and the public and private sectors working to retain the United States’ lead in medical device development and innovation. In addition, Douglas serves on the board of directors for the Battelle Memorial Institute as well as BioOhio, and he is a member of the Ohio Medical Corridor initiative. Formerly, he was executive vice president, chief scientific officer, and a member of the board of management of Aventis, heading drug innovation and approval, with responsibilities for research, development, and regulatory and marketing support. At the Massachusetts Institute of Technology (MIT), Douglas founded and served as first executive director of the MIT Center for Biomedical Innovation. A recipient of numerous awards, Douglas recently was honored as a Geoffrey Beene Gives Back® and GQ magazine 2010 Rock Star of Science™. He holds a doctorate in physical chemistry and a medical degree from Cornell University. | ||||||||
| 448 | Eric D. Kodish, M.D. (February 2017) | Eric D. Kodish is the director of the Center for Ethics, Humanities and Spiritual Care at Cleveland Clinic, where he is the F.J. O’Neill professor and chairman of bioethics. He is executive director of the Cleveland Fellowship in Advanced Bioethics and professor of pediatrics at the Lerner College of Medicine of Case Western Reserve University. Kodish trained in pediatrics at Children’s Memorial Hospital and in medical ethics and pediatric hematology and oncology at the University of Chicago. From 1993 to 2004, he cared for children with cancer and blood diseases at Rainbow Babies and Children’s Hospital, where he also was the founding director of the Rainbow Center for Pediatric Ethics. He has been principal investigator on a series of three NIH-funded multisite studies of informed consent in childhood cancer. Kodish served as chair of the Bioethics Committee of the Children’s Oncology Group from 2002 to 2008, as a member of the Committee on Bioethics of the American Academy of Pediatrics from 1999 to 2005, and as a director-at-large of the Association of Bioethics Program Directors from 2008 to 2010. He also has served on the NIH Recombinant DNA Advisory Committee, the Institute of Medicine’s Committee on Safe and Effective Medicines for Children, and the National Cancer Institute’s Pediatric Central Institutional Review Board. Kodish currently chairs the board of trustees of the Northeast Ohio Medical University. He is an author on more than 100 peer-reviewed publications and the editor of Ethics and Research with Children: A Case-Based Approach (Oxford University Press, 2005). | ||||||||
| 446 | Bernard H. Munos, M.B.A. (February 2017) | Bernard H. Munos founded the InnoThink Center for Research in Biomedical Innovation, a consultancy that focuses on pharmaceutical innovation. He previously served as an advisor for corporate strategy at Eli Lilly and Company, where he focused on disruptive innovation and the radical redesign of research and development. Several of Munos’ research papers — in Nature and Science — have helped stimulate a broad rethinking of the pharmaceutical business model by industry, investors, policymakers, regulators and patient advocates. His work has been profiled by Forbes magazine, and FiercePharma named him one of the 25 most influential people in biopharmaceuticals today. Munos received his master’s degree in business administration from Stanford University and holds graduate degrees in agricultural economics and animal science from the University of California, Davis, and the Paris Institute of Technology for Life, Food and Environmental Sciences. |
Last updated on